Prognostic determinants in patients with uterine and ovarian clear carcinoma (Q37988298)

26 August 2017

Prognostic determinants in patients with uterine and ovarian clear carcinoma (English)

1 reference

26 August 2017

J Alejandro Rauh-Hain

1

1 reference

26 August 2017

Dina Winograd

2

1 reference

26 August 2017

Whitfield B Growdon

3

1 reference

26 August 2017

John O Schorge

4

1 reference

26 August 2017

A K Goodman

5

1 reference

26 August 2017

David M Boruta

6

1 reference

26 August 2017

Ross S Berkowitz

7

1 reference

26 August 2017

Neil S Horowitz

8

1 reference

26 August 2017

Marcela G Del Carmen

9

1 reference

26 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

125

1 reference

26 August 2017

2

1 reference

26 August 2017

376-380

1 reference

Ovarian clear cell adenocarcinoma

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clinical characteristics of clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Thromboembolic complications in patients with clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Treatment issues in clear cell carcinoma of the ovary: a different entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Precursors of endometrial clear cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Clear cell carcinoma of the ovary: a study of 59 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

Targeted therapies for rare gynaecological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.02.016

10.1016/J.YGYNO.2012.02.016

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference